Viral Infections

Intelence Gains Pediatric HIV-1 Indication

Janssen Therapeutics announced that the FDA has approved Intelence (etravirine) tablets to be administered in combination with other antiretroviral (ARV) medications for treatment of human immunodeficiency virus 1 (HIV-1) in treatment-experienced pediatric patients (6-<18 years old) who are experiencing virologic failure with HIV-1 strains resistant to a non-nucleoside reverse transcriptase inhibitor (NNRTI) and other ARVs.